Author Correction: Effects of switching from intravitreal injection of aflibercept to faricimab on ocular blood flow in patients with diabetic macular edema
Yoshinari Saima, Harumasa Yokota, Akifumi Kushiyama, Junya Hanaguri, Akira Ohno, Koyo Takase, Ruri Sugiyama, Kimimasa Muranaka, Satoru Yamagami, Taiji Nagaoka
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsRetinal Diseases and Treatments · Retinal and Optic Conditions · Retinal Imaging and Analysis
Correction to: Scientific Reports 10.1038/s41598-024-63435-8, published online 14 June 2024
The original version of this Article contained an error in the Methods section, where the Intravitreal Aflibercept Injection (IVA) was incorrectly given as Intravitreal Faricimab (IVF).
As a result,
‘In the present study, “treatment resistance” was defined as improvement in retinal thickness by less than 10% at 3 months after the last IVF injection.’
now reads,
‘In the present study, “treatment resistance” was defined as improvement in retinal thickness by less than 10% at 3 months after the last IVA injection.’
The original Article has been corrected.